Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981499 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01981499 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 31 participants.
The verdict
NCT01981499, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
PF-05180999 is a phosphodiesterase-2 inhibitor that is hypothesized to be able to reduce vascular permeability. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and effects on histamine-induced wheal of single doses of PF-05180999 in healthy adult subjects. Histamine-induced wheals are biomarkers of vascular permeability.
Interventions
- DRUG Placebo
- DRUG PF-05180999
- DRUG 120 mg MR PF-05180999
- DRUG 360 mg MR PF-05180999
- DRUG 10 mg cetirizine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01981499
The ClinicalTrials.gov registry entry for NCT01981499 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01981499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01981499 about?
NCT01981499 is a clinical study titled "A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults". PF-05180999 is a phosphodiesterase-2 inhibitor that is hypothesized to be able to reduce vascular permeability. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and effects on histamine-induced wheal of single doses of PF-05180999 in healthy adult subjects. Histam...
What is the current status of trial NCT01981499?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2014-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01981499?
The interventions under investigation include: Placebo (DRUG), PF-05180999 (DRUG), 120 mg MR PF-05180999 (DRUG), 360 mg MR PF-05180999 (DRUG), 10 mg cetirizine (DRUG).
Who is sponsoring clinical trial NCT01981499?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.